Multiple sclerosis (MS) is a heterogeneous disease. With several disease modifying treatments of different
mechanisms of action in use now and in development, it is important to identify reliable biomarkers
to identify those higher risk MS patients in whom stronger but riskier treatments might be used, as well as
to identify those for whom safer treatments of lower efficacy would be sufficient.